Navigation Links
Positive Mosquito Count for West Nile Virus Lead DEP, Southeastern PA Counties to Ramp up Treatment Activities
Date:8/18/2008

NORRISTOWN, Pa., Aug. 18 /PRNewswire-USNewswire/ -- Due to an exceptionally high number of West Nile virus-infected mosquitoes in southeastern Pennsylvania, the Department of Environmental Protection and its county partners will be stepping up efforts this week to combat the mosquito populations that have -- or are most likely to carry -- the virus.

While only one human case of the West Nile virus has been confirmed this year (a 27-year-old Montgomery County woman), DEP's southeast regional director said the conditions merit additional treatments.

"With nearly 70 percent of the state's infected mosquitoes here in the southeast region, we're taking coordinated action to reduce this threat," said Joseph A. Feola. "In order to protect the public, DEP is temporarily reassigning certified pesticide applicators from other parts of the state so that we can be more aggressive in our treatment efforts."

Residents of Bucks, Delaware, Montgomery and Philadelphia counties should expect more frequent mosquito sprayings during the evening hours by state and county West Nile virus staff.

Only those areas with mosquitoes that are capable of carrying the virus will be sprayed.

Spraying activities conducted by DEP will be reported to the media and will be posted at http://www.westnile.state.pa.us/NewsReleases.

Typically, spraying for mosquitoes occurs during the evening in targeted areas with truck-mounted equipment, which dispenses Biomist 3 + 15, a permethrin insecticide product, at a rate of 0.75 ounces per acre.

Certain mosquito species carry the West Nile virus, which, when transmitted to people, can cause West Nile encephalitis, an infection that can result in an inflammation of the brain.

According to the Centers for Disease Control and Prevention, all residents in areas where virus activity has been identified are at risk of getting West Nile
'/>"/>

SOURCE Pennsylvania Department of Environmental Protection
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
2. NewCardio Announces Positive Results From Third Clinical Validation Study
3. Bronchitol Cystic Fibrosis Dose Trial Results Positive
4. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
5. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
6. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
7. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
8. New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
9. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
10. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
11. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2008)...s innovation leadership and long-term commitment t...Nov. 24 Schering-Plough ...al update on boceprevir, its lead investigational ...hase III development. The company believes bocepr...best-in-class protease inhibitor for treating chro...
(Date:11/24/2008)...v. 24 Schering-Plough Co...denant, its novel and selective adenosine2a recept... II dose-finding trial in patients suffering from ...g motor fluctuations and abnormal involuntary move...nted today at the company,s 2008 R&D Update me...
(Date:11/24/2008)...Nov. 24 GeneThera, Inc.,...gin offering its Real Time,PCR test for Johne,s d..., GeneThera is set to begin offering its Jo...of 2009. According to GeneThera Chairman, Dr. Ton... real time PCR test for Johne,s disease,called H...
(Date:11/24/2008).... 24 Medarex, Inc. (Nas...hase 1b clinical trial for MDX-1106 (ONO-4538: dev...fully human anti-PD-1 antibody for the treatment o... pathway may play an important role in tumor evasi...lso promote the persistence of certain chronic vir...
Breaking Medicine Technology:Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer 2Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer 3Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer 4Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 1Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 2Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 3New class of drug offers hope to treatment resistant AIDS patients 777 1New class of drug offers hope to treatment resistant AIDS patients 777 2New class of drug offers hope to treatment resistant AIDS patients 777 3Dendreon Secures 24130 Million Committed Equity Financing Facility 1236 1Dendreon Secures 24130 Million Committed Equity Financing Facility 1236 2Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 1234 1Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 1234 2Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 1234 3
... HOUSTON--(BUSINESS WIRE)--May 23, 2007 - CytoGeni...n, Chief Scientific Officer will,present an update...using the Company,s proprietary synDNA(TM) technol... in Malaga, Spain between May 23,and May 25., Dr. ...ts of,synDNA(TM) based vaccines in mice, rabbits a...
... EVANSTON, Ill.--(BUSINESS WIRE)--May 23, 2007 - N...ed today results of its,pivotal Phase III trauma t...oxygen-carrying red blood cell substitute. The,tri...he treatment,of life-threatening red blood cell lo...s are not available, not for use,interchangeably w...
Other Medicine Technology:CytoGenix to Present at 2007 International DNA Vaccines Conference,in Spain 2Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 2Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 3Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 4Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 5Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 6Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 7Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 8
(Date:12/1/2008)...alysis of the National Cancer Institute,s cancer r...r women experience delayed or incomplete radiation...d that this suboptimal care can lead to worse outc... Medical College and colleagues found that among a...breast cancer registry patients aged 65 and older,...
(Date:12/1/2008)...D, Mass., Dec. 1 MassMutual Retire...ts to support its increasing nonprofit business. N...mpared to last year. , , Dan Darby joined ...alist for the Western region. He reports to M. Pal... market, for MassMutual,s Retirement Services Divi...
(Date:12/1/2008)...f., Dec. 1 Senetek PLC,...ny engaged in the,development of technologies tha...today that Dynamics Group AG, specialists in the f...agement and research with offices in Zurich,Bern... Company. , The Research Report, available ...
(Date:12/1/2008)...ing, steroids effective against plantar fasciitis...HealthDay News) -- Italian researchers say they,ve...nt for the painful foot condition known as plantar...ing" and steroid injections guided by ultrasound, ...ercent success rate in tackling a condition that a...
Breaking Medicine News(10 mins):Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3
...man holds the hand of a little boy, looking at a r...e area, which was in wreck two years ago, washed a...am village is exuding life now. Along the innocent...h of Chennai, India, new casurina saplings are kne...
...round the corner and this is the time to make new ...7 ?// Health watchers suggest- give yourself ...and food intake the whole year-round. Limiting...very important step, if you want to keep your hear...
...t Mayo Clinic have successfully isolated nanoparti...d have isolated proteins, RNA and DNA that appear ..., which appear in the December issue of the Journa...ficant because it is one step closer in solving th...
...Research Service (ARS) scientists have reported th...s of wheat have been found to produce flour with 2...ard J. Souza, research leader of the ARS Soft Whea...io and colleagues Mary J. Guitteri and Karen M. Pe...
Other Medicine News:Health News:Tsunami-Hit Coastal Regions Needs More Relief 2Health News:Gift Yourself A Healthy Heart 2Health News:Link Between Nanoparticles and Kidney Stones 2Health News:Link Between Nanoparticles and Kidney Stones 3
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL.
Kinetic and endpoint methods for the quantitative determination of creatinine in serum.
For the quantitative determination of creatinine in serum. Fixed Time Reaction measured at 540 nm. Linearity: 25 mg/dl. Express Kit with Ready-to-Use Liquid.
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C.
Medicine Products: